Use of adenovirus in vaccines for HIV

Handbook of Experimental Pharmacology

Volumn 188, Issue , 2009, Pages 275-293

  Patterson, Steven ^a   Papagatsias, Timos ^b   Benlahrech, Adel ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MEMBRANE COFACTOR PROTEIN; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PLACEBO; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; RECOMBINANT VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOSTIMULATION; INFECTION PREVENTION; INTERFERON PRODUCTION; LYMPHOCYTE ACTIVATION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS RECOMBINANT; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY; METHODOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; VIROLOGY;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION; VACCINES, SYNTHETIC;

EID: 60549084404     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-71029-5_13     Document Type: Review

References (102)

1. Albinsson B, Kidd AH (1999) Adenovirus type 41 lacks an RGD alpha(v)-integrin binding motif on the penton base and undergoes delayed uptake in A549 cells. Virus Res 64:125-136
2. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
3. Barchet W, Price JD, Cella M, Colonna M, MacMillan SK, Cobb JP, Thompson PA, Murphy KM, Atkinson JP, Kemper C (2006) Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood 107:1497-1504
4. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA, Lifton MA, Chakrabarti BK, Xu L, Nabel GJ, Letvin NL (2003) Plasmid chemokines and colonystimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77:8729-8735
5. Barratt-Boyes SM, Soloff AC, Gao W, Nwanegbo E, Liu X, Rajakumar PA, Brown KN, Robbins PD, Murphey-Corb M, Day RD, Gambotto A (2006) Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J Gen Virol 87:139-149
6. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323
7. Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283-1288
8. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-6110
9. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3:205-211
10. Bruce CB, Akrigg A, Sharpe SA, Hanke T, Wilkinson GW, Cranage MP (1999) Replicationdeficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol 80:2621-2628
11. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, Robert-Guroff M (1997) An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71:8531-8541
12. Buge SL, Murty L, Arora K, Kalyanaraman VS, Markham PD, Richardson ES, Aldrich K, Patterson LJ, Miller CJ, Cheng SM, Robert-Guroff M (1999) Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 73:7430-7440
13. Burgert HG, Ruzsics Z, Obermeier S, Hilgendorf A, Windheim M, Elsing A (2002) Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269:273-318
14. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS (1998) Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 161:5607-5613
15. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77:6305-6313
16. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194:1638-1649
17. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS.Pathog 3:e25 Christensen ML (1989) Human viral gastroenteritis. Clin Microbiol Rev 2:51-89
18. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238
19. DiPaolo N, Ni S, Gaggar A, Strauss R, Tuve S, Li ZY, Stone D, Shayakhmetov D, Kiviat N, Toure P, Sow S, Horvat B, Lieber A (2006) Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther 13:756-765
20. Dorig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295-305
21. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T, Akira S, Reise Sousa C (2003) Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33:827-833
22. Fallaux FJ, Bout A, van dV I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9:1909-1917
23. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, Ertl HC, Wilson JM (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75:11603-11613
24. Favier AL, Burmeister WP, Chroboczek J (2004) Unique physicochemical properties of human enteric Ad41 responsible for its survival and replication in the gastrointestinal tract. Virology 322:93-104
25. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW (2001) Polymercoated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 8:341-348
26. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, Giles-Davis W, Wilson JM, Ertl HC (2003) A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170:1416-1422
27. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408-1412
28. Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174:2185-2189
29. Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan M, Wu V, Pechan P, Kaleko M (1999) Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol 73:6048-6055
30. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95:2509-2514
31. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388-3393
32. Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG (1995) Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 25:3467-3473
33. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863-869
34. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-4655
35. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G (2001) Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31:3026-3037
36. Kuwata T, Igarashi T, Ido E, Jin M, Mizuno A, Chen J, Hayami M (1995) Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. J Gen Virol 76:2181-2191
37. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM (2008) Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82:546-554
38. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ (2003) Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77:10078-10087
39. Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG (2007) Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25:2074-2084
40. Leopold PL, Kreitzer G, Miyazawa N, Rempel S, Pfister KK, Rodriguez-Boulan E, Crystal RG (2000) Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther 11:151-165
41. Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, Korioth-Schmitz B, Yu F, Rohne D, Martin KL, Miura A, Kong WP, Yang ZY, Gelman RS, Golubeva OG, Montefiori DC, Mascola JR, Nabel GJ (2004) Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78:7490-7497
42. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT (2005) Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+T cells. Nature 434:1148-1152
43. LinigerM, Zuniga A, Naim HY (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6:255-266
44. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murthy SC, Chanda PK, Nigida SM, Jr., Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS, Jr., Arthur LO, Mizutani S, Davis A, Hung PP, Gallo RC, Eichberg J, Robert-Guroff M (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3:651-658
45. Malkevitch N, Rohne D, Pinczewski J, Aldrich K, Kalyanaraman VS, Letvin NL, Robert-Guroff M (2004) Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques. AIDS Res Hum Retroviruses 20:235-244
46. Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL (2005) Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 79:771-779
47. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA (1998) Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72:164-169
48. McChesneyMB, Oldstone MB (1989) Virus-induced immunosuppression: infections with measles virus and human immunodeficiency virus. Adv Immunol 45:335-380
49. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200:761-770
50. Mitani K, Graham FL, Caskey CT, Kochanek S (1995) Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 92:3854-3858
51. Miyazawa N, Crystal RG, Leopold PL (2001) Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol 75:1387-1400
52. Molinier-Frenkel V, Prevost-Blondel A, Hong SS, Lengagne R, Boudaly S, Magnusson MK, Boulanger P, Guillet JG (2003) The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J Biol Chem 278:37175-37182
53. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, Takayama T, Logar AJ, Robbins PD, Falo LD, Thomson AW (2000) Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 74:9617-9628
54. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH (2005) Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 79:14161-14168
55. Natuk RJ, Lubeck MD, Chanda PK, Chengalvala M,Wade MS, Murthy SC,Wilhelm J, Vernon SK, Dheer SK, Mizutani S (1993) Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 9:395-404
56. Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, Goeken RM, Goldstein S, Hirsch VM, Martin MA (2004) Highly pathogenic SHIVs and SIVs target different CD4+T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 101:12324-12329
57. O'Riordan CR, Lachapelle A, Delgado C, Parkes V,Wadsworth SC, Smith AE, Francis GE (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10:1349-1358
58. Okada N, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Saito T, Fujita T, Yamamoto A, Hayakawa T, Mayumi T (2001) Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 282:173-179
59. Olive M, Eisenlohr L, Flomenberg N, Hsu S, Flomenberg P (2002) The adenovirus capsid protein hexon contains a highly conserved human CD4+T-cell epitope. Hum Gene Ther 13:1167-1178
60. Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yuksel S, Osterhaus AD, Havenga MJ (2004) An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22:3035-3044
61. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL (1996) A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93:13565-13570
62. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M (2004) Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus- SIV multigene vaccine priming and subunit boosting. J Virol 78:2212-2221
63. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M (2005) Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79:10200-10209
64. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459
65. Philpott NJ, Nociari M, Elkon KB, Falck-Pedersen E (2004) Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci USA 101:6200-6205
66. Pieniazek NJ, Slemenda SB, Pieniazek D, Velarde J, Jr., Luftig RB (1990) Human enteric adenovirus type 41 (Tak) contains a second fiber protein gene. Nucleic Acids Res 18:1901
67. Prevec L, Christie BS, Laurie KE, Bailey MM, Graham FL, Rosenthal KL (1991) Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acquir Immune Defic Syndr 4:568-576
68. Ranieri E, Herr W, Gambotto A, Olson W, Rowe D, Robbins PD, Kierstead LS, Watkins SC, Gesualdo L, Storkus WJ (1999) Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol 73:10416-10425
69. Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE, Melief CJ, Offringa R (1999) Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 73:10245-10253
70. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC (2004) Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 78:7392-7399
71. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243
72. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ (1998) The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72:7909-7915
73. Roth MD, Cheng Q, Harui A, Basak SK, Mitani K, Low TA, Kiertscher SM (2002) Helperdependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol 169:4651-4656
74. Rozis G, de Silva S, Benlahrech A, Papagatsias T, Harris J, Gotch F, Dickson G, Patterson S (2005) Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines. Eur J Immunol 35:2617-2626
75. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P (1999) CD46 is a cellular receptor for human herpesvirus 6. Cell 99:817-827
76. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, Chakrabarti BK, Huang Y, Yang ZY, Mascola JR, Nabel GJ, Letvin NL (2005) Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79:6516-6522
77. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860
78. Schoggins JW, Gall JG, Falck-Pedersen E (2003) Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo. J Virol 77:1039-1048
79. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigenspecific T-cell responses. J Immunother 1997 27:191-200
80. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, Sambor A, Chakrabarti BK, Huang Y, Bailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL (2005) Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79:2956-2963
81. Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar A, Gharwan H, Lieber A (2003) The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 77:3712-3723
82. Shiver JW, Emini EA (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55:355-372
83. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335
84. Smith A, Santoro F, Di Lullo G, Dagna L, Verani A, Lusso P (2003) Selective suppression of IL-12 production by human herpesvirus 6. Blood 102:2877-2884
85. Smith CA, Woodruff LS, Rooney C, Kitchingman GR (1998) Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 9:1419-1427
86. Smith SG, Patel PM, Selby PJ, Jackson AM(2001) The response of human dendritic cells to recombinant adenovirus, recombinant Mycobacterium bovis Bacillus Calmette Guerin and biolistic methods of antigen delivery: different induction of contact-dependant and soluble signals. Immunol Lett 76:79-88
87. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH (2004) Neutralizing antibodies and CD8+T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78:2666-2673
88. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174:7179-7185
89. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, Lin SW, Bian A, Xiang ZQ, Iparraguirre A, Lopez-Camacho C, Wherry EJ, Ertl HC (2007) Adenoviral vectors persist in vivo and maintain activated CD8+T cells: implications for their use as vaccines. Blood 110:1916-1923
90. Vinner L, Wee EG, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC, Hanke T, Fomsgaard A (2003) Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (B×08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol 84:203-213
91. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77:8263-8271
92. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, Berman PW (1986) Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324:572-575
93. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319
94. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA (2006) Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203:1249-1258
95. Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, Merritt R, Hackett NR, Rovelink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG (2004) Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 78:2572-2580
96. Yang Y, Ertl HC, Wilson JM (1994) MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433-442
97. Yang Y, Li Q, Ertl HC,Wilson JM(1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69:2004-2015
98. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77:799-803
99. Yeh HY, Pieniazek N, Pieniazek D, Gelderblom H, Luftig RB (1994) Human adenovirus type 41 contains two fibers. Virus Res 33:179-198
100. Yoshida T, Okuda K, Xin KQ, Tadokoro K, Fukushima J, Toda S, Hagiwara E, Hamajima K, Koshino T, Saito T (2001) Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. Clin Exp Immunol 124:445-452
101. Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, Casimiro D (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13:311-320
102. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM (1999) Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29:964-972